Comparative Pharmacology
Head-to-head clinical analysis: DILANTIN 125 versus FELBAMATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILANTIN 125 versus FELBAMATE.
DILANTIN-125 vs FELBAMATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin stabilizes neuronal membranes by promoting voltage-gated sodium channel inactivation, reducing high-frequency neuronal firing and seizure propagation.
Felbamate enhances GABAergic transmission and inhibits NMDA receptor activity, likely through interaction with the glycine recognition site.
300-400 mg per day orally in divided doses (e.g., 100 mg three times daily); loading dose 1 g orally divided into three doses given at 2-hour intervals, then 100 mg every 6-8 hours for first 24 hours.
1200-3600 mg/day orally in 3-4 divided doses; initiate at 1200 mg/day and titrate by 600-1200 mg/day every 2 weeks.
None Documented
None Documented
Terminal half-life: 7-42 hours (mean 22 hours) in adults; dose-dependent due to saturable metabolism. Steady-state reached in 7-10 days.
Clinical Note
moderateFelbamate + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Felbamate."
Clinical Note
moderateFelbamate + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Felbamate."
Clinical Note
moderateFelbamate + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Felbamate."
Clinical Note
moderateFelbamate + Clotrimazole
Terminal elimination half-life: 13-23 hours in adults (mean ~20 hours); may be prolonged to 30-40 hours in patients with hepatic impairment or those on enzyme inhibitors; clinical context: requires twice-daily dosing; steady-state reached in 4-5 days
Renal: 70% as metabolites (mainly HPPA glucuronide and sulfate), 5-10% as unchanged drug. Fecal: 30% (minor).
Renal: approximately 90% (40-50% unchanged, remainder as metabolites including p-hydroxyfelbamate, 2-hydroxyfelbamate, and felbamate monocarbamate); fecal < 5%
Category C
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Clotrimazole can be decreased when combined with Felbamate."